Research Paper Volume 13, Issue 24 pp 25799—25845
DNA methylation of ARHGAP30 is negatively associated with ARHGAP30 expression in lung adenocarcinoma, which reduces tumor immunity and is detrimental to patient survival
Figure 3. Overall survival curves, recurrence-free survival curves, and disease-free survival curves of ARHGAP30 in lung adenocarcinoma. The blue curves represent patients with lung adenocarcinoma with low ARHGAP30 expression, and the red curves represent patients with lung adenocarcinoma with high ARHGAP30 expression. (A1, A2) Two overall survival curves (in months and days, respectively) from the GEPIA database; (B1, B2) Two disease-free survival (DFS) curves for ARHGAP30 in the GEPIA database (in months and days, respectively). (C–J) Eight overall survival curves from the databases of Oncolnc, Ualcan, UCSC, TCGAportal, TISIDB, KMplot, TIMER, and Linkedomics, respectively. (K1, K2) Two survival curves representing the overall survival curves from the PrognoScan database. (L1, L2) Two survival curves representing recurrence-free survival curves from the PrognoScan database.